Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits
Eisa N, Barood O
Endocrine Practice (2026) · n=25,847
A 17-RCT, 25,847-patient meta-analysis pooling tirzepatide's multi-organ outcomes: cardiovascular non-inferiority versus dulaglutide (HR 0.92), 38% reduction in HFpEF death-or-HF-event (HR 0.62), MASH resolution in 62% (RR 5.33), 21.9-event/hour drop in apnea-hypopnea index, 5.8 mm Hg SBP reduction, +1.5 mL/min/year eGFR preservation, and 32.9% hsCRP reduction.
Eisa and Barood synthesise tirzepatide's randomised-trial evidence across 10 health domains beyond its primary obesity / T2D indications. The meta-analysis pooled 17 RCTs of ≥24 weeks duration covering 25,847 participants, with random-effects modelling, Cochrane RoB 2 risk-of-bias assessment, and GRADE certainty-of-evidence rating.
The headline numerical findings as quoted: tirzepatide demonstrated cardiovascular non-inferiority to dulaglutide for major adverse cardiovascular events (HR 0.92, 95% CI 0.83–1.02). In HFpEF participants, the composite of cardiovascular death or heart-failure events was reduced by 38% (HR 0.62, 95% CI 0.41–0.95). Additional pooled outcomes: MASH resolution in 62% of patients (RR 5.33), clinically significant apnea-hypopnea index reduction of 21.9 events/hour, systolic blood pressure reduction of 5.8 mm Hg, triglyceride reduction of 19.6%, eGFR preservation of +1.5 mL/min/year, and hsCRP reduction of 32.9%. The certainty of evidence was rated moderate-to-high overall.
The conclusion frames tirzepatide as "a comprehensive cardiometabolic protective agent" while explicitly flagging that findings for HFpEF and MASH resolution rely on a small number of constituent trials and require cautious interpretation.
The meta-analysis is dominated by the SURPASS and SURMOUNT trial families — heavy overlap in author groups and Eli Lilly funding across the included trials, and the analysis does not stratify by sponsorship or risk-of-bias domain. The HFpEF outcome is driven by SUMMIT (Packer 2025), a single large trial; the MASH resolution claim (RR 5.33, 62% resolution) is based on the SYNERGY-NASH trial alone — both are one-trial-dominant pooled estimates.
The cardiovascular non-inferiority finding (HR 0.92) is the SURPASS-CVOT comparison against dulaglutide rather than placebo, and dulaglutide itself is a GLP-1 RA — so the absolute cardiovascular benefit versus a true placebo arm is not directly evaluated. The pooled estimates aggregate across heterogeneous populations (T2D, obesity without T2D, HFpEF, MASH), inflating apparent generalisability. The 24-week minimum cut-off is short for renal and cardiovascular outcomes that typically require multi-year follow-up. Abstract-only extraction.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.